Groupama Asset Managment Takes $19.52 Million Position in Haemonetics Co. (NYSE:HAE)

Groupama Asset Managment acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 250,000 shares of the medical instruments supplier's stock, valued at approximately $19,520,000. Groupama Asset Managment owned 0.50% of Haemonetics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Whittier Trust Co. acquired a new stake in Haemonetics in the 4th quarter valued at $62,000. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares during the last quarter. KBC Group NV increased its position in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Haemonetics in the 3rd quarter worth about $204,000. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

HAE has been the subject of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective for the company. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Stock Performance

Shares of NYSE:HAE traded down $1.42 during mid-day trading on Friday, reaching $60.80. The company had a trading volume of 1,019,545 shares, compared to its average volume of 670,392. The company's 50-day moving average price is $65.01 and its 200-day moving average price is $74.27. Haemonetics Co. has a one year low of $58.80 and a one year high of $97.97. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.